ALX1-11 (drug)
Проводит Shire
Страница компанииAn 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00172133/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 45 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1683 чел. во всех странах исследования.
- Центров в реестре: 2 в одном городе. Список — ниже на странице.
- Плановая дата окончания (04.2005) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 51
Критерии включения
- Women who completed 18 months of treatment in Protocol ALX1-11-93001; or
- Women prematurely discontinued from Protocol ALX1-11-93001 who want to participate in OLES for the events listed below must have their clinical course reviewed and approved by the CAB for enrollment into the OLES:
- Clinical or incident lumbar vertebral fractures as assessed by the central imaging organization
- Clinical or incident hip fracture
- Confirmed bone loss at A/P lumbar vertebra or total hip or femoral neck as assessed by the central imaging organization
- Body weight below 40 kg
- Development of an exclusion criterion in Protocol ALX1-11-93001
- It must be accepted by patients whose clinical courses are reviewed by the CAB that participation in OLES may require additional tests at baseline and/or during the study to ensure their utmost safety.
- Women with the ability to self-administer a daily injection or have a designee who will give the injections;
- Women who are capable of understanding and giving written, voluntary informed consent before the start of open-label dosing with ALX1-11.
Критерии невключения
- A. History or Concurrent Illness:
- Disorders of Immunity Endocrine system Gastrointestinal system Kidney and collecting system Liver, biliary tract and pancreatic systems Musculoskeletal system
- Patients with chronic, active joint disease requiring more than one intra-articular injection every 6 months Neoplasia
- Patients who have had squamous or basal cell carcinoma of the skin may enter this study if:
- The lesion(s) were fully resected with clear margins described in a written report by a pathologist, and
- The patient has had no recurrence of lesions for at least one year from the time of the original resection.
- Nervous system Vascular, respiratory and cardiac system *Significant diseases or disorders are determined by history, physical exam or laboratory tests and judged by the Principal Investigator to be significant.
- B. Concurrent Medication:
- Patients may not use any of the following therapies while they are enrolled in this OLES without permission from the Sponsor and the PMO:
- Tetracycline antibiotics for four weeks prior to bone biopsy
- Any PTH analogs \[e.g., rhPTH(1-84), PTH(1-34), PTHrP and analogs\]
- Fluoride
- Strontium
- Phenytoin for seizure control
- Any investigational drug other than ALX1-11
- Anabolic steroids or androgens
- Active Vitamin D3 metabolites and analogs, e.g., calcitriol
- Systemic corticosteroids, more than 5 mg/day prednisone or a systemic corticosteroid formulation equivalent to 5 mg/day prednisone
- 1\. A patient who has been enrolled into the OLES and needs to receive an acute bolus of steroids (oral or injectable) for a self-limited illness may continue treatment in the study if the following requirements are met:
- Exposure to steroids will be limited to no more than 30 consecutive days
- The maximal dose of steroid (prednisone equivalent) must be limited to no more than 225 mg (7.5 mg each day for 30 days)
- The illness is acute in nature and is not expected to recur during the remaining period of the study
- Bisphosphonates, including investigational bisphosphonates
- Calcitonin
- Estrogen replacement therapy by oral, transdermal or intramuscular administration
- SERM drugs, e.g., tamoxifen, raloxifene, Evista
- Vaginal application of estrogen-containing creams unless the dose is:
- conjugated estrogen or estradiol: maximum of 0.5 g twice each week (total of 1.0 g weekly)
- Estrace (Ogen): maximum of 1.0 g twice each week (total of 2.0 g weekly)
- Daily inhaled corticosteroid unless dose is equivalent to <1200 µg/day of beclomethasone
- Cytostatics, e.g., azathioprine, recombinant human tumor necrosis fusion (Fc) protein, monoclonal antibody against tumor necrosis factor (e.g., remicade \[infliximab\]
- Methotrexate
- The antimetabolite, methotrexate, which interferes with DNA synthesis, repair and cellular replication should not be used by patients participating in this OLES.
- In general, immunomodulatory agents with antiproliferative activity are not permitted as a concomitant medication in this OLES.
- Intra-articular injections
- 1\. Patients may receive a maximum of one intra-articular injection (ONE JOINT ONLY) every 6 months while participating in this OLES. The joint that is injected may be a different joint every 6 months. The dose of corticosteroid injected should not exceed the anti-inflammatory equivalent dose of Prednisone 40 mg suspension. The dose and volume should be adjusted downward as appropriate to the size of the joint.
- Provera is an acceptable concomitant medication when used according to the label instructions
- Patients may be enrolled in this OLES if they have been stabilized on the following therapy for the specified amount of time:
- Thyroid Hormone (<0.1 mg/day thyroxine) therapy for at least 6 months If taking > 0.1 mg/day but < 0.2 mg/day, must have serum TSH level 1. > 0.1mU/L. Patients will be excluded if they are taking doses of > 0.2 mg/day.
- 2\. However, if a patient has had a minimal change in L-thyroxine dose of < 0.025 mg/day within 6 months of the baseline visit, and has been on this new dose for at least 2 months, the patient may be enrolled in this study. The patient's history with L-thyroxine must be clearly documented in the source documents.
- 3\. If a patient requires an increase in their thyroid replacement dose, as recommended by a physician who is caring for the patient, after enrollment in this OLES, the patient must have a TSH and T4 level within 3 months of the dose change to ensure the patient does not become hyperthyroid
- Stable dosage of thiazide for at least 3 consecutive months
- C. Laboratory Values and Physical Examination Findings:
- \- Serum calcium greater than 10.7 mg/dL (2.66 mmol/L) at baseline will be managed as outlined in Appendix 4
- \- Urinary calcium to creatinine ratio greater than or equal to 1 at baseline will be managed as outlined in Appendix 5
- Elevated total serum alkaline phosphates (> 400 U/L) at baseline will be managed as outlined in Appendix 6 except as noted for Latin and South American countries.
- Any other clinically significant abnormal value as judged by the investigator
- D. Substance Abuse:
- Alcohol and/or drug abuse
- E. Compliance:
- Suspected or confirmed poor compliance in completing clinical trial evaluations and/or clinical trial required questionnaires
Источник: ClinicalTrials.gov, NCT00172133 · запись обновлена в реестре 17 мая 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 1
- To evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1-11-93001 (TOP). — 24 months of treatment
Цель исследования
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human parathyroid hormone, rhPTH(1-84), on vertebral fracture incidence. The primary objective of this study is to evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1 11 93001.
Где проходит
2 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00172133 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.